Candida species: Current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options

Página do item simplificado
dc.contributor.authorSardi, J. C. O. [UNESP]
dc.contributor.authorScorzoni, L. [UNESP]
dc.contributor.authorBernardi, T. [UNESP]
dc.contributor.authorFusco-Almeida, A. M. [UNESP]
dc.contributor.authorMendes-Giannini, Maria José Soares [UNESP]
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2014-05-27T11:27:30Z
dc.date.available2014-05-27T11:27:30Z
dc.date.issued2013-01-01
dc.description.abstractThe incidence of fungal infections has increased significantly, so contributing to morbidity and mortality. This is caused by an increase in antimicrobial resistance and the restricted number of antifungal drugs, which retain many side effects. Candida species are major human fungal pathogens that cause both mucosal and deep tissue infections. Recent evidence suggests that the majority of infections produced by this pathogen are associated with biofilm growth. Biofilms are biological communities with a high degree of organization, in which micro-organisms form structured, coordinated and functional communities. These biological communities are embedded in a self-created extracellular matrix. Biofilm production is also associated with a high level of antimicrobial resistance of the associated organisms. The ability of Candida species to form drugresistant biofilms is an important factor in their contribution to human disease. The study of plants as an alternative to other forms of drug discovery has attracted great attention because, according to the World Health Organization, these would be the best sources for obtaining a wide variety of drugs and could benefit a large population. Furthermore, silver nanoparticles, antibodies and photodynamic inactivation have also been used with good results. This article presents a brief review of the literature regarding the epidemiology of Candida species, as well as their pathogenicity and ability to form biofilms, the antifungal activity of natural products and other therapeutic options. © 2013 SGM.en
dc.description.affiliationDepartment of Clinical Analysis, Laboratory of Clinical Mycology Faculty of Pharmaceutical Sciences UNESP, Araraquara
dc.description.affiliationUnespDepartment of Clinical Analysis, Laboratory of Clinical Mycology Faculty of Pharmaceutical Sciences UNESP, Araraquara
dc.format.extent10-24
dc.identifierhttp://dx.doi.org/10.1099/jmm.0.045054-0
dc.identifier.citationJournal of Medical Microbiology, v. 62, n. PART1, p. 10-24, 2013.
dc.identifier.doi10.1099/jmm.0.045054-0
dc.identifier.issn0022-2615
dc.identifier.orcid0000-0002-8059-0826
dc.identifier.scopus2-s2.0-84871118785
dc.identifier.urihttp://hdl.handle.net/11449/74215
dc.identifier.wosWOS:000315607800002
dc.language.isoeng
dc.relation.ispartofJournal of Medical Microbiology
dc.relation.ispartofjcr2.112
dc.relation.ispartofsjr0,914
dc.rights.accessRightsAcesso restrito
dc.sourceScopus
dc.subjectadhesin
dc.subjectamphotericin B
dc.subjectanidulafungin
dc.subjectantifungal agent
dc.subjectcaspofungin
dc.subjectcinnamon extract
dc.subjectCoriandrum sativum extract
dc.subjectechinocandin
dc.subjectessential oil
dc.subjectfluconazole
dc.subjectflucytosine
dc.subjectitraconazole
dc.subjectketoconazole
dc.subjectmicafungin
dc.subjectmiconazole
dc.subjectnystatin
dc.subjectposaconazole
dc.subjectsilver nanoparticle
dc.subjectterconazole
dc.subjectusnic acid
dc.subjectvoriconazole
dc.subjectantifungal activity
dc.subjectartificial ventilation
dc.subjectbiofilm
dc.subjectCandida
dc.subjectCandida albicans
dc.subjectCandida dubliniensis
dc.subjectCandida glabrata
dc.subjectCandida metapsilosis
dc.subjectCandida orthopsilosis
dc.subjectCandida parapsilosis
dc.subjectCandida rugosa
dc.subjectCandida tropicalis
dc.subjectcandidemia
dc.subjectcandidiasis
dc.subjectClavispora lusitaniae
dc.subjectcritically ill patient
dc.subjectextracellular matrix
dc.subjectfungal colonization
dc.subjectfungal community
dc.subjectfungal virulence
dc.subjectfungus isolation
dc.subjecthemodialysis
dc.subjecthuman
dc.subjectincidence
dc.subjectintensive care unit
dc.subjectintestine flora
dc.subjectmedical device
dc.subjectmononuclear phagocyte
dc.subjectneutrophil
dc.subjectnonhuman
dc.subjectphotodynamics
dc.subjectPichia guilliermondii
dc.subjectpriority journal
dc.subjectreview
dc.subjectsystemic mycosis
dc.subjectAntifungal Agents
dc.subjectBiofilms
dc.subjectBiological Agents
dc.subjectCandidiasis
dc.subjectHumans
dc.titleCandida species: Current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic optionsen
dc.typeArtigo
dcterms.licensehttp://www.sgmjournals.org/site/misc/open_access.xhtml
unesp.author.lattes3716273524139678[4]
unesp.author.orcid0000-0002-8059-0826[5]
unesp.author.orcid0000-0002-2115-8988[4]
unesp.campusUniversidade Estadual Paulista (Unesp), Faculdade de Ciências Farmacêuticas, Araraquarapt

Arquivos

Coleções

Artigos - Análises Clínicas - FCFAR